Marta Peciña1, Jiazhou Chen2, Thandi Lyew3, Jordan F Karp4, Alexandre Y Dombrovski3. 1. Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania. Electronic address: pecinam@upmc.edu. 2. National Institutes of Health, Bethesda, Maryland; The Faculty of Brain Sciences, Division of Psychology and Language Sciences, University College London, London, United Kingdom. 3. Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania. 4. Department of Psychiatry, University of Arizona, Tucson, Arizona.
Abstract
BACKGROUND: Like placebo analgesia, the antidepressant placebo effect appears to involve cortical and subcortical endogenous opioid signaling, yet the mechanism through which opioid release affects mood remains unclear. The orbitofrontal cortex (OFC)-which integrates various attributes of a stimulus to predict associated outcomes-has been implicated in placebo effects and is rich in μ opioid receptors. We hypothesized that naltrexone blockade of μ opioid receptors would blunt OFC-dependent antidepressant placebo effects. METHODS: Twenty psychotropic-free patients with major depressive disorder completed a randomized, double-blind, placebo-controlled crossover study of 1 oral dose of 50 mg of naltrexone or matching placebo immediately before completing 2 sessions of the antidepressant placebo functional magnetic resonance imaging task. This task manipulates placebo-associated expectancies and their reinforcement while assessing expected and actual mood improvement. RESULTS: Behaviorally, manipulations of antidepressant placebo expectancies and their reinforcement had positive, interactive effects on participants' expectancy and mood ratings. The high-expectancy condition recruited the dorsolateral and ventrolateral prefrontal cortex, as well as dorsal attention stream regions. Interestingly, increased dorsolateral and ventrolateral prefrontal cortex brain responses appeared to attenuate the antidepressant placebo effect. The administration of 1 oral dose of naltrexone, compared with placebo, partially abolished the interaction of the expectancy and reinforcement manipulation on mood and blocked reinforcement-induced responses in the right central OFC. CONCLUSIONS: Our results show preliminary evidence for the role of μ opioid central OFC modulation in antidepressant placebo effects by positively biasing the value of placebo based on reinforcement and enhancing subsequent hedonic experiences.
BACKGROUND: Like placebo analgesia, the antidepressant placebo effect appears to involve cortical and subcortical endogenous opioid signaling, yet the mechanism through which opioid release affects mood remains unclear. The orbitofrontal cortex (OFC)-which integrates various attributes of a stimulus to predict associated outcomes-has been implicated in placebo effects and is rich in μ opioid receptors. We hypothesized that naltrexone blockade of μ opioid receptors would blunt OFC-dependent antidepressant placebo effects. METHODS: Twenty psychotropic-free patients with major depressive disorder completed a randomized, double-blind, placebo-controlled crossover study of 1 oral dose of 50 mg of naltrexone or matching placebo immediately before completing 2 sessions of the antidepressant placebo functional magnetic resonance imaging task. This task manipulates placebo-associated expectancies and their reinforcement while assessing expected and actual mood improvement. RESULTS: Behaviorally, manipulations of antidepressant placebo expectancies and their reinforcement had positive, interactive effects on participants' expectancy and mood ratings. The high-expectancy condition recruited the dorsolateral and ventrolateral prefrontal cortex, as well as dorsal attention stream regions. Interestingly, increased dorsolateral and ventrolateral prefrontal cortex brain responses appeared to attenuate the antidepressant placebo effect. The administration of 1 oral dose of naltrexone, compared with placebo, partially abolished the interaction of the expectancy and reinforcement manipulation on mood and blocked reinforcement-induced responses in the right central OFC. CONCLUSIONS: Our results show preliminary evidence for the role of μ opioid central OFC modulation in antidepressant placebo effects by positively biasing the value of placebo based on reinforcement and enhancing subsequent hedonic experiences.
Authors: Helen S Mayberg; J Arturo Silva; Steven K Brannan; Janet L Tekell; Roderick K Mahurin; Scott McGinnis; Paul A Jerabek Journal: Am J Psychiatry Date: 2002-05 Impact factor: 18.112
Authors: Bret R Rutherford; Melanie M Wall; Patrick J Brown; Tse-Hwei Choo; Tor D Wager; Bradley S Peterson; Sarah Chung; Irving Kirsch; Steven P Roose Journal: Am J Psychiatry Date: 2016-09-09 Impact factor: 18.112
Authors: Nathan T M Huneke; Ibrahim H Aslan; Harry Fagan; Naomi Phillips; Rhea Tanna; Samuele Cortese; Matthew Garner; David S Baldwin Journal: Int J Neuropsychopharmacol Date: 2022-06-21 Impact factor: 5.678